Predictive stability moves into the mainstream
In April 2025, the International Council for Harmonisation (ICH) released for public comments a draft of its consolidated Q1 guideline on the stability testing of drug substances and drug products. The revision consolidates the long-standing Q1A through Q1F series and the biologics-focused Q5C into a single, modern framework. For the first time, the consolidated ICH Q1 draft gives stability modelling its own dedicated annex, creating a clearer home for predictive stability approaches within the global stability framework.
A dedicated annex on stability modeling sets out how mathematical and statistical models can be used to predict stability outcomes and support real-time data. It explicitly recognizes that such techniques can now be used in place of traditional, long-term stability studies in regulatory filings. Although predictive stability approaches have been accepted in prior filings, the lack of specific ICH guidance left review expectations less consistent across applications and regions. In many cases, health authorities relied on traditional ICH stability guidelines, which could slow down review and approval of clinical and market applications. The new ICH Q1 draft gives stability modelling a clearer framework for how predictive stability can be incorporated into filings.
What this means for drug development teams
The ICH draft guidance supports a more modern science- and risk-based approach to assigning shelf life. It asks sponsors to pre-specify their models, justify their assumptions, and verify predictions against observed stability data. This is precisely how ASAPprime® has been applied for years: using defined study designs, statistical modelling, model justification, and comparison with available real-time or accelerated data to determine shelf life. Teams already using ASAPprime® are well positioned with the direction ICH Q1 is taking, not scrambling to catch up with it.
For early-stage programs, this reinforces the approach of using predictive stability that has long been used for use-period assignment for investigational products. The new guideline strengthens the scientific and regulatory footing for that approach. For commercial and post-approval work, ASAPprime® continues to serve as a rigorous tool for justifying shelf life and bridging product changes.
Where things stand
ICH Q1 is still in draft form. Public consultation closed in 2025, and final adoption is anticipated in the 2026-2027 timeframe. FreeThink is tracking the guideline as it advances through the ICH process and will continue to support customers in applying ASAPprime® in line with evolving expectations. The core message for drug developers is optimistic: predictive stability is being written into global standards, and ASAPprime® is an established way to put that approach into practice.
_______________________________________________________________________________________________________________
About FreeThink Technologies
FreeThink Technologies is a contract research organization specializing in accelerated drug development services. Our Molecule-to-Clinic platform integrates API development, preclinical development, clinical manufacturing, and regulatory strategy to help pharmaceutical companies advance drug candidates efficiently.
Founded in 2011, FreeThink’s Branford, Connecticut laboratories conduct experimental work to help companies develop formulations, establish analytical methods, and solve complex problems. FreeThink also develops and licenses ASAPprime®, the leading stability software package for determining shelf life under highly accelerated conditions.
Contact: info@freethinktech.com | +1 860 237 5800 | freethinktech.com
Services: API Development | Drug Development Services | Preclinical Development | Clinical Manufacturing | Pharmaceutical Research | GMP Manufacturing